The meteoric rise of GLP-1 medications for diabetes and weight management has created an unexpected safety challenge that extends beyond their biological effects. Analysis of over 112,000 adverse event reports reveals a troubling pattern of user errors that coincided precisely with supply shortages beginning in late 2022.
FDA adverse event data spanning nearly a decade shows GLP-1 drugs generated administration-related problems in 63% of reported incidents, substantially higher than the 39% seen with injectable insulin. Most concerning, dosing errors and administration mistakes for GLP-1 medications spiked dramatically starting in Q4 2022 and continued climbing through 2024—exactly matching the timeline of widespread drug shortages. Insulin products showed no such pattern, suggesting the problem stems from GLP-1-specific factors rather than general injection difficulties.
This correlation likely reflects the perfect storm created when desperate patients turned to compounded versions, unfamiliar formulations, or improvised dosing schedules during shortages. Unlike insulin, which patients typically use for years under close medical supervision, many GLP-1 users are newcomers navigating complex injection protocols without adequate preparation. The findings highlight a critical gap in the healthcare system's ability to safely scale revolutionary treatments. While the biological promise of GLP-1 drugs remains strong, the data suggests that rapid adoption without corresponding infrastructure for patient education creates preventable harm. As supplies normalize, the focus must shift from drug availability to ensuring users can safely navigate these powerful medications.